CellEDIT - CRISPR-Edited HeLa Cell Line
Let us support you with a custom and high-quality engineered HeLa cell line.
We’ll handle the CRISPR editing of your HeLa cells, so you can focus on your next discoveries.
HeLa cells represent the first immortal human cells to be grown in culture and are the basis for countless significant scientific breakthroughs. The cells were isolated in 1951 from a cervical carcinoma derived from a 31-year-old patient.
HeLa Cell Line Information
Organism
Human
Tissue Type
Uterus; Cervix
Cell Type
Epithelial
Disease
Adenocarcinoma
Donor Information
Age
31
Gender
Female
Ethnicity
African American
HeLa Cell Line Applications
Cancer Research: HeLa cells are extensively used to study the biology of cancer, including tumor growth, metastasis, and the effects of various cancer treatments.
Virology: These cells are a critical tool in virology research, helping scientists understand the life cycles of viruses, how viruses infect cells, and the cellular responses to viral infections. HeLa cells have been instrumental in the development of vaccines, including the polio vaccine.
Genetic Research: HeLa cells are used to explore gene function, regulation, and expression, making them valuable for understanding genetic diseases and developing gene therapies.
Drug Testing and Development: The cell line is commonly used in high-throughput screening assays to evaluate the efficacy and toxicity of new pharmaceutical compounds, aiding in the drug discovery and development process.
Toxicology Studies: HeLa cells are utilized to assess the cytotoxic effects of various chemicals and environmental agents, providing insights into their safety and potential health risks.
Related Case Studies
Advance your research with CellEDIT’s expertise. A custom engineered HeLa cell line is a cornerstone of biological research due to its remarkable ability to proliferate indefinitely, providing a consistent and reliable model for studying cancer biology. It has been pivotal in virology, contributing to significant breakthroughs like the development of the polio vaccine. Additionally, HeLa cells are widely used in genetic research, drug testing, and toxicology studies, making them invaluable for advancing medical and scientific knowledge. With the CellEDIT workflow and within 10 weeks, we can support you with custom and monoclonal knockout HeLa cell lines, suited for your project needs.
Efficient on
Hard-to-transfect cells
Vector-free
direct intra-nuclear delivery
Minimized Off-Target
Immortalized Cells
Learn how the CellEDIT workflow was used to generate 5 monoclonal HPRT knockouts in C2C12 cell line through direct intra-nuclear injection of only 51 cells.
Hard-to-Transfect Cells
Discover how
the CellEDIT workflow was used to produce 3 monoclonal HPRT1 knockouts in SK-MES-1 cell, a notoriously hard-to-transfect cell line.
Available Edits using CellEDIT Engineered Cells
Knockout
Save time in the lab by empowering your research with CellEDIT. Confidently streamline your drug discovery workflow and investigate gene function with effective CRISPR knockouts.
Multiplex Editing
At CellEDIT, we provide you with multiplexed cell lines in 10 weeks. The efficiency and gentleness of our vector-free editing through intra-nuclear delivery, makes it an ideal system to perform multiplex gene editing in one go.
Related Resources
Educational
Technical
Introduction to CRISPR Knockout Gene Editing with CellEDIT
An Overview of CellEDIT' CRISPR Cell Line Development Services
CellEDIT' CRISPR Cell Line Development Workflow
CellEDIT's Engineered Cell Lines
CRISPR-Engineered U2OS Cell Line
CRISPR-Engineered MDA MB 231 Cell Line
CRISPR-Engineered A549 Cell Line
CRISPR-Edited Hek293 Cell Line
CRISPR-Engineered C2C12 Cell Line
Media & Downloads
On-Demand CellEDIT's CRISPR Cell Line Engineering Webinar
CellEDIT's Application Note n*1 - Introducing the CellEDIT Workflow
CellEDIT's Application Note n*2 - Overcoming the hard-to-transfect cell line hurdle
Open Access Publication featuring CellEDIT: Antony, Justin S., Anabel Migenda Herranz, Tahereh Mohammadian Gol, Susanne Mailand, Paul Monnier, Jennifer Rottenberger, Alicia Roig‐Merino et al. " Accelerated generation of gene-engineered monoclonal CHO cell lines using FluidFM nanoinjection and CRISPR/Cas9" Biotechnology Journal 19, no. 4 (2024): 2300505.
Case Study - Streamlined U2OS Cell Line Modification with the CellEDIT Service Workflow, featuring our CellEDIT Customer: Dr. Kanstantsin Siniuk.